News Business Extraction International Medical
Prati-Donaduzzi secures largest global pharma supply agreement with API manufacturer Brains Bioceutical

(Globe Newswire) Vancouver — Brains Bioceutical Corp., the largest natural cannabinoid active pharmaceutical ingredient (API) manufacturer in the world, has signed a landmark supply agreement with Prati-Donaduzzi, one of the largest drug manufacturers in South America, to supply natural EU-GMP CBD API for their ongoing clinical trials and cannabinoid products approved by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s Health Regulatory Agency.

“We have built a very strong foundation via our renowned science team and commercial production capability to produce the world’s purest natural sourced cannabinoid API molecules. Accordingly, we are thrilled that this has allowed us to expand our long-standing relationship with an industry leader, Prati-Donaduzzi. This supply agreement is a landmark moment in the history of the pharmaceutical cannabinoids industry. This outcome is the culmination of respective efforts as leading innovators in the space. This makes Brains Bio an important partner for Prati-Donaduzzi as they continue to lead and pave the way in cannabinoid medicines and cannabinoid science,” — Ricky Brar CEO and chairperson, Brains Bioceutical

This landmark deal for both companies represents a significant step forward in developing natural cannabinoid-based medicines in the global pharmaceutical industry. Brains Bio is a cutting-edge manufacturer of natural cannabinoid APIs, with the largest cannabinoid API production facility in the world, built for global capacity to supply customers throughout their drug development lifecycle and subsequent commercialization of their future cannabinoid-based market-authorized drugs.

Prati-Donaduzzi is a leader in the pharmaceutical industry in South America, with a reputation for innovation and excellence in drug manufacturing and pharmaceutical development. The company has one of the largest portfolios of generic drugs in Brazil and supplies both South American and global markets. They are also the largest distributor of cannabinoid-based medicines in South America, having conducted over five years of research and development in cannabinoid innovation and drug development.

Brains Bio is equally committed to advancing the development of cannabinoid-based medicines and supporting clinical trials and advancements in cannabinoid science via the Brains Bio cannabinoid science platform and the company’s newly opened state-of-the-art production facility, designed to deliver the highest standard cannabinoid APIs to the pharmaceutical industry.

Cannabinoid-based medicines have enormous potential to revolutionize the treatment of a wide range of medical conditions. In recent years, there has been a growing demand for these medicines, and the global market for cannabinoid-based drugs is projected to reach $56 billion by 2026.

Brains Bio is proud to be at the forefront of this industry, providing high-quality natural cannabinoid APIs that will enable pharmaceutical companies like Prati-Donaduzzi to develop and deliver new and innovative treatments to patients around the world.

This landmark long term supply agreement is a significant milestone for both companies and reflects the growing demand for cannabinoid-based medicines in the global pharmaceutical industry. Brains Bio is proud to be at the forefront of this industry and looks forward to continuing to collaborate with leading players like Prati-Donaduzzi. This follows and is accretive Brains Bio’s previous press release announcing the supply to Prati-Donaduzzi, of its natural CBD API for Brazil’s first approved medical cannabis product.